DAIICHI SANKYO, INC.

DAIICHI SANKYO, INC. logo
🇺🇸United States
Ownership
Subsidiary
Established
2010-01-01
Employees
10K
Market Cap
$79B
Website
http://daiichisankyo.us

Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

Phase 3
Recruiting
Conditions
Interventions
First Posted Date
2024-08-29
Last Posted Date
2024-12-05
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
700
Registration Number
NCT06578247
Locations
🇺🇸

City of Hope Phoenix, Goodyear, Arizona, United States

🇺🇸

Mayo Clinic - Phoenix, Phoenix, Arizona, United States

🇺🇸

University of Arizona Cancer Center, Tucson, Arizona, United States

and more 97 locations

Study on Prevalence and Impact of Brain Metastases on Survival in Lung Cancer by Line of Treatment

First Posted Date
2024-08-16
Last Posted Date
2024-12-09
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
22517
Registration Number
NCT06557967
Locations
🇺🇸

ConcertAI Database, Cambridge, Massachusetts, United States

Real-World Pharmacological Treatment Pattern of Neuropathic Pain in China

First Posted Date
2024-08-09
Last Posted Date
2024-12-18
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
1000
Registration Number
NCT06546202
Locations
🇨🇳

Sun Yat-Sen University Cancer Center, Guangzhou City, China

🇨🇳

China-Japan Friendship Hospital, Beijing, China

🇨🇳

Beijing Hospital, Beijing, China

and more 6 locations

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

First Posted Date
2024-04-12
Last Posted Date
2024-11-22
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
123
Registration Number
NCT06362252
Locations
🇺🇸

University of Alabama -Birmingham, Birmingham, Alabama, United States

🇺🇸

David Geffen School of Medicine, Los Angeles, California, United States

🇺🇸

Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States

and more 46 locations

A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

First Posted Date
2024-03-26
Last Posted Date
2024-11-21
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
520
Registration Number
NCT06330064
Locations
🇺🇸

Los Angeles Cancer Network, Los Angeles, California, United States

🇺🇸

Valkyrie Clinical Trials, Los Angeles, California, United States

🇺🇸

Pih Health Hematology Medical Oncology, Whittier, California, United States

and more 102 locations

Medical Access Program for Datopotamab Deruxtecan in NSCLC Patients

First Posted Date
2024-02-28
Last Posted Date
2024-11-06
Lead Sponsor
Daiichi Sankyo
Registration Number
NCT06279728
Locations
🇪🇸

Hospital Clinico Universitario Lozano Blesa, Zaragoza, Spain

🇪🇸

Hospital Universitario Miguel Servet, Zaragoza, Spain

🇨🇭

Hopitaux Universitaires Genève (HUG), Geneva, Switzerland

and more 110 locations

A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors

First Posted Date
2024-02-06
Last Posted Date
2024-06-18
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
210
Registration Number
NCT06244485
Locations
🇺🇸

The Cleveland Clinic Foundation, Cleveland, Ohio, United States

🇺🇸

Valkyrie Clinical Trials, Los Angeles, California, United States

🇺🇸

Brcr Medical Center, Inc Dba Boca Raton Clinical Research, Plantation, Florida, United States

and more 21 locations

A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)

First Posted Date
2024-01-18
Last Posted Date
2024-10-02
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
800
Registration Number
NCT06210776
Locations
🇨🇳

Peking University First Hospital, Beijing, China

🇨🇳

China-Japan Friendship Hospital, Beijing, China

🇨🇳

Peking University Shougang Hospital, Beijing, China

and more 35 locations

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

First Posted Date
2024-01-12
Last Posted Date
2024-12-04
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
540
Registration Number
NCT06203210
Locations
🇺🇸

Providence Medical Foundation, Fullerton, California, United States

🇺🇸

David Geffen School of Medicine, Los Angeles, California, United States

🇺🇸

Highlands Oncology Group, Springdale, Arkansas, United States

and more 226 locations

A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)

Phase 3
Recruiting
Conditions
Interventions
First Posted Date
2023-12-18
Last Posted Date
2024-12-16
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
50
Registration Number
NCT06174987
Locations
🇺🇸

Miami Cancer Institute, Miami, Florida, United States

🇺🇸

Duke University - Trent Center, Durham, North Carolina, United States

🇦🇺

Flinders Medical Center, Bedford Park, Australia

and more 22 locations
© Copyright 2024. All Rights Reserved by MedPath